{"id":"gdc-229","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hyperglycemia"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GDC-229 works by inhibiting the PI3K enzyme, which is involved in cell signaling pathways. This inhibition can lead to the reduction of cancer cell growth and proliferation.","oneSentence":"GDC-229 is a small molecule targeting the PI3K pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:50.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic triple-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT03091777","phase":"PHASE3","title":"Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis","status":"COMPLETED","sponsor":"Balmoral Medical company","startDate":"2017-03-10","conditions":"Bacterial Vaginosis","enrollment":871}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GDC-229","genericName":"GDC-229","companyName":"Balmoral Medical company","companyId":"balmoral-medical-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GDC-229 is a small molecule targeting the PI3K pathway. Used for Metastatic triple-negative breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}